CTLA4 and non-small cell lung carcinoma: Targeting co-inhibitory signals beyond PD-1/PD-L1 may help overcome resistance, but with the exception of combined treatment directed against PD-1/PD-L1 and CTLA4, the experience in NSCLC is limited.